Medical therapy of stricturing Crohn's disease: What the gut can learn from other organs - a systematic review

Fibrogenesis and Tissue Repair

Volumn 7, Issue 1, 2014, Pages

  Bettenworth, Dominik ^a   Rieder, Florian ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anti fibrotic agents; Crohn's disease; Intestinal fibrosis; Organ fibrosis

Indexed keywords

ANGIOTENSIN II; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RENIN; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; COLITIS; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENDOSCOPIC THERAPY; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; INTESTINAL FIBROSIS; INTESTINE OBSTRUCTION; INTESTINE STENOSIS; INTESTINE SURGERY; KIDNEY FIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; RECURRENCE RISK; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURGICAL APPROACH; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84899730068     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-7-5     Document Type: Review

References (198)

1. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012, 380:1590-1605. 10.1016/S0140-6736(12)60026-9, 22914295.
2. Cheifetz AS. Management of active Crohn disease. JAMA 2013, 309:2150-2158. 10.1001/jama.2013.4466, 23695484.
3. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011, 140:1785-1794. 10.1053/j.gastro.2011.01.055, 21530745.
4. Lenze F, Wessling J, Bremer J, Ullerich H, Spieker T, Weckesser M, Gonschorrek S, Kannengiesser K, Rijcken E, Heidemann J, Luegering A, Schober O, Domschke W, Kucharzik T, Maaser C. Detection and differentiation of inflammatory versus fibromatous Crohn's disease strictures: prospective comparison of 18 F-FDG-PET/CT, MR-enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. Inflamm Bowel Dis 2012, 18:2252-2260. 10.1002/ibd.22930, 22359277.
5. Schoepfer AM, Safroneeva E, Vavricka SR, Peyrin-Biroulet L, Mottet C. Treatment of fibrostenotic and fistulizing Crohn's disease. Digestion 2012, 86(Suppl 1):23-27.
6. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, . ACCENT I Study Group Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549. 10.1016/S0140-6736(02)08512-4, 12047962, ACCENT I Study Group.
7. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239. 10.1136/gut.2006.106781, 2701613, 17299059.
8. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65. 10.1053/j.gastro.2006.11.041, 17241859.
9. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241. 10.1136/gut.2004.045294, 1774826, 15647188.
10. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn's disease complicated by strictures: a systematic review. Gut 2013, 62:1072-1084. 10.1136/gutjnl-2012-304353, 23626373.
11. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol 2008, 24:462-468. 10.1097/MOG.0b013e3282ff8b36, 18622160.
12. Hassan C, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A, Taggi F, Winn S, Morini S. Systematic review: endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther 2007, 26:1457-1464. 10.1111/j.1365-2036.2007.03532.x, 17903236.
13. Thienpont C, D'Hoore A, Vermeire S, Demedts I, Bisschops R, Coremans G, Rutgeerts P, Van Assche G. Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut 2010, 59:320-324. 10.1136/gut.2009.180182, 19840991.
14. Singh VV, Draganov P, Valentine J. Efficacy and safety of endoscopic balloon dilation of symptomatic upper and lower gastrointestinal Crohn's disease strictures. J Clin Gastroenterol 2005, 39:284-290. 10.1097/01.mcg.0000155128.31208.44, 15758621.
15. Hoffmann JC, Heller F, Faiss S, von Lampe B, Kroesen AJ, Wahnschaffe U, Schulzke JD, Zeitz M, Bojarski C. Through the endoscope balloon dilation of ileocolonic strictures: prognostic factors, complications, and effectiveness. Int J Colorectal Dis 2008, 23:689-696. 10.1007/s00384-008-0461-9, 18338175.
16. Froehlich F, Juillerat P, Pittet V, Felley C, Mottet C, Vader JP, Michetti P, Gonvers JJ. Maintenance of surgically induced remission of Crohn's disease. Digestion 2007, 76:130-135. 10.1159/000111027, 18239404.
17. Despott EJ, Gupta A, Burling D, Tripoli E, Konieczko K, Hart A, Fraser C. Effective dilation of small-bowel strictures by double-balloon enteroscopy in patients with symptomatic Crohn's disease (with video). Gastrointest Endosc 2009, 70:1030-1036. 10.1016/j.gie.2009.05.005, 19640518.
18. Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C. Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease. Aliment Pharmacol Ther 2012, 36:151-158. 10.1111/j.1365-2036.2012.05146.x, 22612326.
19. Wibmer AG, Kroesen AJ, Grone J, Buhr HJ, Ritz JP. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn's disease-review of the literature. Int J Colorectal Dis 2010, 25:1149-1157. 10.1007/s00384-010-1010-x, 20628881.
20. Baba S, Nakai K. Strictureplasty for Crohn's disease in Japan. J Gastroenterol 1995, 30(Suppl 8):135-138.
21. Ambe R, Campbell L, Cagir B. A comprehensive review of strictureplasty techniques in Crohn's disease: types, indications, comparisons, and safety. J Gastrointest Surg 2012, 16:209-217. 10.1007/s11605-011-1651-2, 21909847.
22. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
23. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009, 30:265-274. 10.1111/j.1365-2036.2009.04033.x, 19438428.
24. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013, 5:167sr1.
25. Fichtner-Feigl S, Young CA, Kitani A, Geissler EK, Schlitt HJ, Strober W. IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008, 135:2003-2013. 10.1053/j.gastro.2008.08.055, 18938165.
26. Zhu MY, Lu YM, Ou YX, Zhang HZ, Chen WX. Dynamic progress of 2,4,6-trinitrobenzene sulfonic acid induced chronic colitis and fibrosis in rat model. J Dig Dis 2012, 13:421-429. 10.1111/j.1751-2980.2012.00607.x, 22788928.
27. Vallance BA, Gunawan MI, Hewlett B, Bercik P, Van Kampen C, Galeazzi F, Sime PJ, Gauldie J, Collins SM. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 2005, 289:G116-G128. 10.1152/ajpgi.00051.2005, 15778431.
28. Mahavadi S, Flynn RS, Grider JR, Qiao LY, Murthy KS, Hazelgrove KB, Kuemmerle JF. Amelioration of excess collagen IalphaI, fibrosis, and smooth muscle growth in TNBS-induced colitis in IGF-I(+/-) mice. Inflamm Bowel Dis 2011, 17:711-719. 10.1002/ibd.21437, 2990779, 20722057.
29. Kumagai S, Ohtani H, Nagai T, Funa K, Hiwatashi NO, Shimosegawa, Nagura H. Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease. Tohoku J Exp Med 2001, 195:21-33. 10.1620/tjem.195.21, 11780721.
30. Lawrance IC, Maxwell L, Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis 2001, 7:226-236. 10.1097/00054725-200108000-00008, 11515849.
31. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012, 18:1028-1040. 10.1038/nm.2807, 3405917, 22772564.
32. Rieder F, Fiocchi C. Intestinal fibrosis in IBD - a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009, 6:228-235. 10.1038/nrgastro.2009.31, 19347014.
33. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006, 12:99-106. 10.1038/nm1332, 16327802.
34. Akiho H, Lovato P, Deng Y, Ceponis PJ, Blennerhassett P, Collins SM. Interleukin-4- and -13-induced hypercontractility of human intestinal muscle cells-implication for motility changes in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2005, 288:G609-G615. 10.1152/ajpgi.00273.2004, 15528258.
35. Bailey JR, Bland PW, Tarlton JF, Peters I, Moorghen M, Sylvester PA, Probert CS, Whiting CV. IL-13 promotes collagen accumulation in Crohn's disease fibrosis by down-regulation of fibroblast MMP synthesis: a role for innate lymphoid cells?. PLoS One 2012, 7:e52332. 10.1371/journal.pone.0052332, 3534115, 23300643.
36. Biancheri P, Di Sabatino A, Ammoscato F, Facciotti F, Caprioli F, Curciarello R, Hoque SS, Ghanbari A, Joe-Njoku I, Giuffrida P, Rovedatti L, Geginat J, Corazza GR, Macdonald TT. Absence of a role for interleukin-13 in inflammatory bowel disease. Eur J Immunol 2014, 44:370-385. 10.1002/eji.201343524, 24338958.
37. Valente AJ, Yoshida T, Gardner JD, Somanna N, Delafontaine P, Chandrasekar B. Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1. Cell Signal 2012, 24:560-568. 10.1016/j.cellsig.2011.10.010, 3339406, 22037550.
38. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, Iwaisako K, Liu X, Zhang M, Osterreicher CH, Stickel F, Ley K, Brenner DA, Kisseleva T. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012, 143:765-776. 10.1053/j.gastro.2012.05.049, 3635475, 22687286.
39. Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL, Iwakura Y, Fujimoto M, Takehara K. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum 2012, 64:3726-3735. 10.1002/art.34643, 22833167.
40. Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG, Wang XX, Liu HZ, Sun W, Hu ZW. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol 2011, 187:3003-3014. 10.4049/jimmunol.1004081, 21841134.
41. Gregory LG, Jones CP, Walker SA, Sawant D, Gowers KH, Campbell GA, McKenzie AN, Lloyd CM. IL-25 drives remodelling in allergic airways disease induced by house dust mite. Thorax 2013, 68:82-90. 10.1136/thoraxjnl-2012-202003, 3534261, 23093652.
42. Biancheri P, Pender SL, Ammoscato F, Giuffrida P, Sampietro G, Ardizzone S, Ghanbari A, Curciarello R, Pasini A, Monteleone G, Corazza GR, Macdonald TT, Di Sabatino A. The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis. Fibrogenesis Tissue Repair 2013, 6:13. 10.1186/1755-1536-6-13, 3733737, 23834907.
43. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP, . Secukinumab in Crohn's Disease Study Group Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700. 10.1136/gutjnl-2011-301668, 22595313, Secukinumab in Crohn's Disease Study Group.
44. Hawinkels LJ, Ten Dijke P. Exploring anti-TGF-beta therapies in cancer and fibrosis. Growth Factors 2011, 29:140-152. 10.3109/08977194.2011.595411, 21718111.
45. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int 1997, 51:1376-1382. 10.1038/ki.1997.188, 9150447.
46. Latella G, Sferra R, Speca S, Vetuschi A, Gaudio E. Can we prevent, reduce or reverse intestinal fibrosis in IBD?. Eur Rev Med Pharmacol Sci 2013, 17:1283-1304.
47. Monteleone G, Pallone F, MacDonald TT. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol 2004, 25:513-517. 10.1016/j.it.2004.07.008, 15364052.
48. McKaig BC, McWilliams D, Watson SA, Mahida YR. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003, 162:1355-1360. 10.1016/S0002-9440(10)63931-4, 1851243, 12651627.
49. Medina C, Santos-Martinez MJ, Santana A, Paz-Cabrera MC, Johnston MJ, Mourelle M, Salas A, Guarner F. Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis. J Pathol 2011, 224:461-472. 10.1002/path.2870, 21465486.
50. Rieder F, Georgieva M, Schirbel A, Artinger M, Zugner A, Blank M, Brenmoehl J, Scholmerich J, Rogler G. Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflamm Bowel Dis 2010, 16:1505-1513. 10.1002/ibd.21255, 20803697.
51. Brittan M, Chance V, Elia G, Poulsom R, Alison MR, MacDonald TT, Wright NA. A regenerative role for bone marrow following experimental colitis: contribution to neovasculogenesis and myofibroblasts. Gastroenterology 1984-1995, 2005:128.
52. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009, 119:1417-1419. 10.1172/JCI39675, 2689122, 19487817.
53. Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 1866-1878, 2003:124.
54. Rieder F, Kessler S, Sans M, Fiocchi C. Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol 2012, 303:G786-G801. 10.1152/ajpgi.00059.2012, 22878121.
55. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124. 10.1038/nature11582, 3491803, 23128233.
56. Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H, . Western Regional Pediatric IBD Research Alliance Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006, 101:360-367. 10.1111/j.1572-0241.2006.00456.x, 2259248, 16454844, Western Regional Pediatric IBD Research Alliance.
57. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, Lopez R, Spector L, Fire E, Yarden J, Rogler G, Dotan N, Klebl F. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 2010, 16:1367-1375. 10.1002/ibd.21179, 20024902.
58. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, Lopez R, Spector L, Fire E, Yarden J, Rogler G, Dotan N, Klebl F. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis 2010, 16:263-274. 10.1002/ibd.21046, 19653286.
59. Geboes KP, Cabooter L, Geboes K. Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis. Acta Gastroenterol Belg 2000, 63:371-376.
60. Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S, Gay R. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 1988, 94:257-265.
61. Borley NR, Mortensen NJ, Kettlewell MG, George BD, Jewell DP, Warren BF. Connective tissue changes in ileal Crohn's disease: relationship to disease phenotype and ulcer-associated cell lineage. Dis Colon Rectum 2001, 44:388-396. 10.1007/BF02234738, 11289285.
62. Geboes K, El-Zine MY, Dalle I, El-Haddad S, Rutgeerts P, Van Eyken P. Tenascin and strictures in inflammatory bowel disease: an immunohistochemical study. Int J Surg Pathol 2001, 9:281-286. 10.1177/106689690100900404, 12574843.
63. Gelbmann CM, Mestermann S, Gross V, Kollinger M, Scholmerich J, Falk W. Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 1999, 45:210-217. 10.1136/gut.45.2.210, 1727598, 10403732.
64. Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatology 2008, 47:1394-1400. 10.1002/hep.22193, 18307210.
65. Ura H, Obara T, Yokota K, Shibata Y, Okamura K, Namiki M. Effects of transforming growth factor-beta released from gastric carcinoma cells on the contraction of collagen-matrix gels containing fibroblasts. Cancer Res 1991, 51:3550-3554.
66. Hinz B. Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr Rheumatol Rep 2009, 11:120-126. 10.1007/s11926-009-0017-1, 19296884.
67. Oikarinen AI, Vuorio EI, Zaragoza EJ, Palotie A, Chu ML, Uitto J. Modulation of collagen metabolism by glucocorticoids. Receptor-mediated effects of dexamethasone on collagen biosynthesis in chick embryo fibroblasts and chondrocytes. Biochem Pharmacol 1988, 37:1451-1462. 10.1016/0006-2952(88)90006-8, 3358778.
68. Ketchum LD, Smith J, Robinson DW, Masters FW. The treatment of hypertrophic scar, keloid and scar contracture by triamcinolone acetonide. Plast Reconstr Surg 1966, 38:209-218. 10.1097/00006534-196609000-00005, 5919604.
69. Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, Ferrozzi F, Corradi D, Salvarani C, Buzio C. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011, 378:338-346. 10.1016/S0140-6736(11)60934-3, 21733570.
70. Badea I, Taylor M, Rosenberg A, Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology (Oxford) 2009, 48:213-221.
71. Peikert T, Daniels CE, Beebe TJ, Meyer KC, Ryu JH, . Interstitial Lung Diseases Network of the American College of Chest Physicians Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med 2008, 102:1342-1348. 10.1016/j.rmed.2008.03.018, 18621518, Interstitial Lung Diseases Network of the American College of Chest Physicians.
72. Graham MF, Willey A, Adams J, Diegelmann RF. Corticosteroids increase procollagen gene expression, synthesis, and secretion by human intestinal smooth muscle cells. Gastroenterology 1995, 109:1454-1461. 10.1016/0016-5085(95)90630-4, 7557125.
73. Kochhar R, Poornachandra KS. Intralesional steroid injection therapy in the management of resistant gastrointestinal strictures. World J Gastrointest Endosc 2010, 2:61-68. 2999060, 21160692.
74. Warnatz K, Keskin AG, Uhl M, Scholz C, Katzenwadel A, Vaith P, Peter HH, Walker UA. Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 2005, 64:828-833. 10.1136/ard.2004.029793, 1755530, 15897305.
75. Rogliani P, Mura M, Assunta Porretta M, Saltini C. New perspectives in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2008, 2:75-93. 10.1177/1753465808089363, 19124361.
76. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004, 23:306-309.
77. Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lemann M, Colombel JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2089-2096, 2009:104.
78. Spinelli A, Correale C, Szabo H, Montorsi M. Intestinal fibrosis in Crohn's disease: medical treatment or surgery?. Curr Drug Targets 2010, 11:242-248. 10.2174/138945010790309984, 19916949.
79. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333. quiz 591, 10.1053/j.gastro.2005.11.030, 16472588.
80. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P, . SONIC Study Group Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395. 10.1056/NEJMoa0904492, 20393175, SONIC Study Group.
81. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Jarnerot G, Hibi T, Rutgeerts P, . PURSUIT-SC Study Group Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146:85-95. 10.1053/j.gastro.2013.05.048, 23735746, PURSUIT-SC Study Group.
82. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, . PRECISE 1 Study Investigators Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238. 10.1056/NEJMoa067594, 17634458, PRECISE 1 Study Investigators.
83. Bahcecioglu IH, Koca SS, Poyrazoglu OK, Yalniz M, Ozercan IH, Ustundag B, Sahin K, Dagli AF, Isik A. Hepatoprotective effect of infliximab, an anti-TNF-alpha agent, on carbon tetrachloride-induced hepatic fibrosis. Inflammation 2008, 31:215-221. 10.1007/s10753-008-9067-1, 18427963.
84. Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, Boumpas DT. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007, 25:23-28.
85. Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008, 75:346-349. 10.1159/000090248, 16369127.
86. Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 2005, 280:36099-36109. 10.1074/jbc.M505291200, 16141211.
87. Di Sabatino A, Pender SL, Jackson CL, Prothero JD, Gordon JN, Picariello L, Rovedatti L, Docena G, Monteleone G, Rampton DS, Tonelli F, Corazza GR, MacDonald TT. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007, 133:137-149. 10.1053/j.gastro.2007.04.069, 17631138.
88. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006, 101:1030-1038. 10.1111/j.1572-0241.2006.00463.x, 16606351.
89. Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soule JC. Infliximab treatment for symptomatic Crohn's disease strictures. Aliment Pharmacol Ther 2009, 29:279-285. 10.1111/j.1365-2036.2008.03887.x, 19035967.
90. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500. 10.1136/gut.2008.155812, 18832518.
91. Yamada M, Kuwano K, Maeyama T, Yoshimi M, Hamada N, Fukumoto J, Egashira K, Hiasa K, Takayama K, Nakanishi Y. Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis. J Clin Pathol 2007, 60:916-920. 1994490, 17018685.
92. Arribillaga L, Dotor J, Basagoiti M, Riezu-Boj JI, Borras-Cuesta F, Lasarte JJ, Sarobe P, Cornet ME, Feijoo E. Therapeutic effect of a peptide inhibitor of TGF-beta on pulmonary fibrosis. Cytokine 2011, 53:327-333. 10.1016/j.cyto.2010.11.019, 21185199.
93. Ezquerro IJ, Lasarte JJ, Dotor J, Castilla-Cortazar I, Bustos M, Penuelas I, Blanco G, Rodriguez C, Lechuga Mdel C, Greenwel P, Rojkind M, Prieto J, Borras-Cuesta F. A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 2003, 22:12-20. 10.1016/S1043-4666(03)00101-7, 12946101.
94. Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2012, 6:107-114. 10.1177/1753465812436663, 22333982.
95. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM, . CAPACITY Study Group Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769. 10.1016/S0140-6736(11)60405-4, 21571362, CAPACITY Study Group.
96. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012, 11:790-811. 10.1038/nrd3810, 3520610, 23000686.
97. Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012, 24:274-280. 10.1097/BOR.0b013e3283524b9a, 22450392.
98. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011, 79:1236-1243. 10.1038/ki.2011.33, 3257033, 21368745.
99. Crunkhorn S. Deal watch: Biogen acquires Stromedix to pursue novel fibrosis therapy. Nat Rev Drug Discov 2012, 11:260.
100. Alan C, Kocoglu H, Altintas R, Alici B, Resit Ersay A. Protective effect of decorin on acute ischaemia-reperfusion injury in the rat kidney. Arch Med Sci 2011, 7:211-216. 3258707, 22291758.
101. Terada Y, Hanada S, Nakao A, Kuwahara M, Sasaki S, Marumo F. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int 2002, 61:S94-S98.
102. Lu A, Miao M, Schoeb TR, Agarwal A, Murphy-Ullrich JE. Blockade of TSP1-dependent TGF-beta activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol 2011, 178:2573-2586. 10.1016/j.ajpath.2011.02.039, 3124297, 21641382.
103. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004, 287:F7-F16. 10.1152/ajprenal.00451.2003, 15180923.
104. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006, 69:213-217. 10.1038/sj.ki.5000054, 16408108.
105. Szabo H, Fiorino G, Spinelli A, Rovida S, Repici A, Malesci AC, Danese S. Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases. Aliment Pharmacol Ther 2010, 31:189-201.
106. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316. 10.1172/JCI200419603, 524221, 15520863.
107. Gordon J, Spiera R. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: the difficulty in interpreting proof-of-concept studies. Int J Rheumatol 2011, 2011:842181. 3195539, 22013450.
108. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, . Imatinib-IPF Study Investigators Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010, 181:604-610. 10.1164/rccm.200906-0964OC, 20007927, Imatinib-IPF Study Investigators.
109. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov 2006, 5:717-718. 10.1038/nrd2135, 17001803.
110. Gordon J, Spiera R. Imatinib and the treatment of fibrosis: recent trials and tribulations. Curr Rheumatol Rep 2011, 13:51-58. 10.1007/s11926-010-0146-6, 21086081.
111. Ferguson MW, Duncan J, Bond J, Bush J, Durani P, So K, Taylor L, Chantrey J, Mason T, James G, Laverty H, Occleston NL, Sattar A, Ludlow A, O'Kane S. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 2009, 373:1264-1274. 10.1016/S0140-6736(09)60322-6, 19362676.
112. Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, Pilling D, Gomer RH, Trial J, Frangogiannis NG, Entman ML. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 2006, 103:18284-18289. 10.1073/pnas.0608799103, 1643845, 17114286.
113. Pilling D, Roife D, Wang M, Ronkainen SD, Crawford JR, Travis EL, Gomer RH. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 2007, 179:4035-4044.
114. Dillingh MR, van den Blink B, Moerland M, van Dongen MG, Levi M, Kleinjan A, Wijsenbeek MS, Lupher ML, Harper DM, Getsy JA, Hoogsteden HC, Burggraaf J. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther 2013, 26:672-676. 10.1016/j.pupt.2013.01.008, 23380438.
115. Latella G, Sferra R, Vetuschi A, Zanninelli G, D'Angelo A, Catitti V, Caprilli R, Gaudio E. Prevention of colonic fibrosis by Boswellia and Scutellaria extracts in rats with colitis induced by 2,4,5-trinitrobenzene sulphonic acid. Eur J Clin Invest 2008, 38:410-420. 10.1111/j.1365-2362.2008.01955.x, 18489401.
116. Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NA, Picariello L, Cazzola P, Monteleone G, Tonelli F, Corazza GR, MacDonald TT, Pender SL. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009, 58:777-789. 10.1136/gut.2008.149096, 19201776.
117. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:506-520. 10.1038/nrc1926, 16794634.
118. Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, Saffitz JE, Doetschman T. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci U S A 1995, 92:12215-12219. 10.1073/pnas.92.26.12215, 40327, 8618872.
119. Kulkarni AB, Ward JM, Yaswen L, Mackall CL, Bauer SR, Huh CG, Gress RE, Karlsson S. Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am J Pathol 1995, 146:264-275. 1870760, 7856732.
120. Boivin GP, Ormsby I, Jones-Carson J, O'Toole BA, Doetschman T. Germ-free and barrier-raised TGF beta 1-deficient mice have similar inflammatory lesions. Transgenic Res 1997, 6:197-202. 10.1023/A:1018490007745, 9167267.
121. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000, 12:171-181. 10.1016/S1074-7613(00)80170-3, 10714683.
122. Nomura M, Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 1998, 393:786-790. 10.1038/31693, 9655392.
123. Yang X, Li C, Xu X, Deng C. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci U S A 1998, 95:3667-3672. 10.1073/pnas.95.7.3667, 19893, 9520423.
124. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen F, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR, . Cat-192 Study Group; Scleroderma Clinical Trials Consortium Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007, 56:323-333. 10.1002/art.22289, 17195236, Cat-192 Study Group; Scleroderma Clinical Trials Consortium.
125. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, Kim SB, Kim YS, Kim J, Bang BK. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004, 286:F46-F57.
126. Chen HC, Guh JY, Shin SJ, Lai YH. Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis 2002, 160:141-146. 10.1016/S0021-9150(01)00545-7, 11755931.
127. Hartner A, Klanke B, Cordasic N, Amann K, Schmieder RE, Veelken R, Hilgers KF. Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension. J Hypertens 2009, 27:376-385. 10.1097/HJH.0b013e32831997d6, 19226708.
128. Watts KL, Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 2004, 287:L1323-L1332. 10.1152/ajplung.00447.2003, 15298857.
129. Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One 2009, 4:e5263. 10.1371/journal.pone.0005263, 2674206, 19421322.
130. Grip O, Janciauskiene S, Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br J Pharmacol 2008, 155:1085-1092. 2597264, 18806816.
131. Burke JP, Watson RW, Murphy M, Docherty NG, Coffey JC, O'Connell PR. Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor beta1-mediated activation of intestinal fibroblasts. Br J Surg 2009, 96:541-551. 10.1002/bjs.6577, 19358180.
132. Abe Y, Murano M, Murano N, Morita E, Inoue T, Kawakami K, Ishida K, Kuramoto T, Kakimoto K, Okada T, Narabayashi K, Umegaki E, Higuchi K. Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis. Dig Dis Sci 2012, 57:335-344. 10.1007/s10620-011-1879-4, 21909991.
133. Haydont V, Bourgier C, Pocard M, Lusinchi A, Aigueperse J, Mathe D, Bourhis J, Vozenin-Brotons MC. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res 2007, 13:5331-5340. 10.1158/1078-0432.CCR-07-0625, 17875761.
134. Ruster C, Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol 2011, 22:1189-1199. 10.1681/ASN.2010040384, 21719784.
135. Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M, Chandrasekar B. Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. J Mol Cell Cardiol 2013, 65:9-18.
136. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodes J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000, 118:1149-1156. 10.1016/S0016-5085(00)70368-4, 10833490.
137. Corey KE, Shah N, Misdraji J, Abu Dayyeh BK, Zheng H, Bhan AK, Chung RT. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 2009, 29:748-753. 10.1111/j.1478-3231.2009.01973.x, 3151254, 19220742.
138. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013, 9:459-469. 10.1038/nrneph.2013.110, 23774812.
139. Daniel C. Blocking of angiotensin II is more than blocking of transforming growth factor-beta. Kidney Int 2008, 74:551-553. 10.1038/ki.2008.290, 18709023.
140. Couluris M, Kinder BW, Xu P, Gross-King M, Krischer J, Panos RJ. Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung 2012, 190:523-527. 10.1007/s00408-012-9410-z, 22810758.
141. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105:2512-2517. 10.1161/01.CIR.0000017264.66561.3D, 12034658.
142. el-Agroudy AE, Hassan NA, Foda MA, Ismail AM, el-Sawy EA, Mousa O, Ghoneim MA. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003, 23:300-306. 10.1159/000072820, 12904684.
143. De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol 2003, 98:1371-1376. 10.1111/j.1572-0241.2003.07497.x, 12818283.
144. Hirasawa K, Sato Y, Hosoda Y, Yamamoto T, Hanai H. Immunohistochemical localization of angiotensin II receptor and local renin-angiotensin system in human colonic mucosa. J Histochem Cytochem 2002, 50:275-282. 10.1177/002215540205000215, 11799146.
145. Jaszewski R, Tolia V, Ehrinpreis MN, Bodzin JH, Peleman RR, Korlipara R, Weinstock JV. Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis. Gastroenterology 1990, 98:1543-1548.
146. Spencer AU, Yang H, Haxhija EQ, Wildhaber BE, Greenson JK, Teitelbaum DH. Reduced severity of a mouse colitis model with angiotensin converting enzyme inhibition. Dig Dis Sci 2007, 52:1060-1070. 10.1007/s10620-006-9124-2, 1866259, 17342403.
147. Sueyoshi R, Ignatoski KM, Daignault S, Okawada M, Teitelbaum DH. Angiotensin converting enzyme-inhibitor reduces colitis severity in an IL-10 knockout model. Dig Dis Sci 2013, 58:3165-3177. 10.1007/s10620-013-2825-4, 23949641.
148. Lee C, Chun J, Hwang SW, Kang SJ, Im JP, Kim JS. Enalapril inhibits nuclear factor-kappaB signaling in intestinal epithelial cells and peritoneal macrophages and attenuates experimental colitis in mice. Life Sci 2014, 95:29-39. 10.1016/j.lfs.2013.11.005, 24239644.
149. Byrnes JJ, Gross S, Ellard C, Connolly K, Donahue S, Picarella D. Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm Res 2009, 58:819-827. 10.1007/s00011-009-0053-3, 19517214.
150. Wengrower D, Zanninelli G, Pappo O, Latella G, Sestieri M, Villanova A, Faitelson Y, Pines M, Goldin E. Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1. Inflamm Bowel Dis 2004, 10:536-545. 10.1097/00054725-200409000-00007, 15472513.
151. Wengrower D, Zanninelli G, Latella G, Necozione S, Metanes I, Israeli E, Lysy J, Pines M, Papo O, Goldin E. Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. Can J Gastroenterol 2012, 26:33-39. 3275403, 22288068.
152. Gieling RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009, 296:G1324-G1331. 10.1152/ajpgi.90564.2008, 2697947, 19342509.
153. Liu X. Inflammatory cytokines augments TGF-beta1-induced epithelial-mesenchymal transition in A549 cells by up-regulating TbetaR-I. Cell Motil Cytoskeleton 2008, 65:935-944. 10.1002/cm.20315, 18792103.
154. Diaz JA, Booth AJ, Lu G, Wood SC, Pinsky DJ, Bishop DK. Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am J Transplant 2009, 9:1773-1783. 10.1111/j.1600-6143.2009.02706.x, 2756490, 19538487.
155. Luckett-Chastain LR, Gallucci RM. Interleukin (IL)-6 modulates transforming growth factor-beta expression in skin and dermal fibroblasts from IL-6-deficient mice. Br J Dermatol 2009, 161:237-248. 10.1111/j.1365-2133.2009.09215.x, 2766075, 19438433.
156. Ito H. IL-6 and Crohn's disease. Curr Drug Targets Inflamm Allergy 2003, 2:125-130. 10.2174/1568010033484296, 14561164.
157. Fichtner-Feigl S, Strober W, Geissler EK, Schlitt HJ. Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis. Mucosal Immunol 2008, 1(Suppl 1):S24-S27. 3673699, 19079223.
158. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, Fatenejad S. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178:948-955. 10.1164/rccm.200709-1446OC, 18669816.
159. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098. 10.1056/NEJMoa1106469, 21812663.
160. Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, Danoff SK, Lechtzin N. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012, 157:398-406. 10.7326/0003-4819-157-6-201209180-00003, 22986377.
161. Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J, Yla-Herttuala S, Fiocchi C, Danese S. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009, 136:585-595. 10.1053/j.gastro.2008.09.064, 19013462.
162. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M, du Bois RM. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087. 10.1056/NEJMoa1103690, 21992121.
163. Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, Levine AD, Blumberg RS, Fiocchi C. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007, 56:1696-1705. 10.1136/gut.2006.116467, 2095703, 17682002.
164. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007, 292:F905-F911.
165. Kim H, Oda T, Lopez-Guisa J, Wing D, Edwards DR, Soloway PD, Eddy AA. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2001, 12:736-748.
166. Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A. Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets 2009, 10:1245-1254. 10.2174/138945009789753264, 19909233.
167. Kofla-Dlubacz A, Matusiewicz M, Krzystek-Korpacka M, Iwanczak B. Correlation of MMP-3 and MMP-9 with Crohn's disease activity in children. Dig Dis Sci 2012, 57:706-712. 10.1007/s10620-011-1936-z, 3282895, 21997756.
168. Faubion WA, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol 1891-1900, 2013:108.
169. Lakatos G, Hritz I, Varga MZ, Juhasz M, Miheller P, Cierny G, Tulassay Z, Herszenyi L. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Dig Dis 2012, 30:289-295. 10.1159/000336995, 22722554.
170. Meijer MJ, Mieremet-Ooms MA, van der Zon AM, van Duijn W, van Hogezand RA, Sier CF, Hommes DW, Lamers CB, Verspaget HW. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007, 39:733-739. 10.1016/j.dld.2007.05.010, 17602907.
171. Meijer MJ, Mieremet-Ooms MA, Sier CF, van Hogezand RA, Lamers CB, Hommes DW, Verspaget HW. Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohn's disease. Inflamm Bowel Dis 2009, 15:84-92. 10.1002/ibd.20581, 18634035.
172. Osman B, Akool el S, Doller A, Muller R, Pfeilschifter J, Eberhardt W. Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease-antiprotease system by the mTOR inhibitor rapamycin. Biochem Pharmacol 2011, 81:134-143. 10.1016/j.bcp.2010.09.011, 20854798.
173. Wang S, Wilkes MC, Leof EB, Hirschberg R. Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010, 298:F142-F149. 10.1152/ajprenal.00320.2009, 2806113, 19846571.
174. Reinisch W, Panes J, Lemann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008, 103:2284-2292. 10.1111/j.1572-0241.2008.02024.x, 18671816.
175. Massey DC, Bredin F, Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 2008, 57:1294-1296. 10.1136/gut.2008.157297, 18719139.
176. Dumortier J, Lapalus MG, Guillaud O, Poncet G, Gagnieu MC, Partensky C, Scoazec JY. Everolimus for refractory Crohn's disease: a case report. Inflamm Bowel Dis 2008, 14:874-877. 10.1002/ibd.20395, 18275074.
177. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med 2013, 19:557-566. 3870016, 23652116.
178. Rousseaux C, Desreumaux P. [The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD)]. J Soc Biol 2006, 200:121-131. 10.1051/jbio:2006015, 17151549.
179. Aoki Y, Maeno T, Aoyagi K, Ueno M, Aoki F, Aoki N, Nakagawa J, Sando Y, Shimizu Y, Suga T, Arai M, Kurabayashi M. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration 2009, 77:311-319. 10.1159/000168676, 18974632.
180. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009, 174:519-533. 10.2353/ajpath.2009.080574, 2630560, 19147827.
181. Bertin B, Dubuquoy L, Colombel JF, Desreumaux P. PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets 2013, 14:1501-1507. 10.2174/13894501113149990162, 23651165.
182. Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, Ohmann C, Gensch K, Ruzicka T. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 2010, 49:1336-1345. 10.1093/rheumatology/keq077, 20371505.
183. King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:92-99. 10.1164/rccm.201011-1874OC, 21474646.
184. Johnson LA, Luke A, Sauder K, Moons DS, Horowitz JC, Higgins PD. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a " Top-Down" approach to intestinal fibrosis in mice. Inflamm Bowel Dis 2012, 18:460-471. 10.1002/ibd.21812, 3206985, 21761511.
185. Govani SM, Stidham RW, Higgins PD. How early to take arms against a sea of troubles? The case for aggressive early therapy in Crohn's disease to prevent fibrotic intestinal strictures. J Crohns Colitis 2013, 7:923-927. 10.1016/j.crohns.2013.06.011, 23880128.
186. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250. 10.1097/00054725-200207000-00002, 12131607.
187. Goodman ZD, Becker RL, Pockros PJ, Afdhal NH. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 2007, 45:886-894. 10.1002/hep.21595, 17393526.
188. Duarte-Rojo A, Altamirano JT, Feld JJ. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Ann Hepatol 2012, 11:426-439.
189. Ryan JD, Silverberg MS, Xu W, Graff LA, Targownik LE, Walker JR, Carr R, Clara I, Miller N, Rogala L, Bernstein CN. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther 2013, 38:274-283. 10.1111/apt.12368, 23725363.
190. Jurickova I, Collins MH, Chalk C, Seese A, Bezold R, Lake K, von Allmen D, Frischer JS, Falcone RA, Trapnell BC, Denson LA. Paediatric Crohn disease patients with stricturing behaviour exhibit ileal granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody production and reduced neutrophil bacterial killing and GM-CSF bioactivity. Clin Exp Immunol 2013, 172:455-465. 10.1111/cei.12076, 23600834.
191. Maglinte DD, Bender GN, Heitkamp DE, Lappas JC, Kelvin FM. Multidetector-row helical CT enteroclysis. Radiol Clin North Am 2003, 41:249-262. 10.1016/S0033-8389(02)00115-X, 12659337.
192. Al-Hawary M, Zimmermann EM. A new look at Crohn's disease: novel imaging techniques. Curr Opin Gastroenterol 2012, 28:334-340.
193. Adler J, Swanson SD, Schmiedlin-Ren P, Higgins PD, Golembeski CP, Polydorides AD, McKenna BJ, Hussain HK, Verrot TM, Zimmermann EM. Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease. Radiology 2011, 259:127-135. 10.1148/radiol.10091648, 3064818, 21324841.
194. Griffin N, Goh V. Functional imaging of the bowel. Abdom Imaging 2013, 38:1203-1213. 10.1007/s00261-013-0030-8, 24008510.
195. Schirin-Sokhan R, Winograd R, Tischendorf S, Wasmuth HE, Streetz K, Tacke F, Trautwein C, Tischendorf JJ. Assessment of inflammatory and fibrotic stenoses in patients with Crohn's disease using contrast-enhanced ultrasound and computerized algorithm: a pilot study. Digestion 2011, 83:263-268. 10.1159/000321389, 21273775.
196. Stidham RW, Xu J, Johnson LA, Kim K, Moons DS, McKenna BJ, Rubin JM, Higgins PD. Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn's disease. Gastroenterology 2011, 141:819-826. 10.1053/j.gastro.2011.07.027, 21784048.
197. Brooker JC, Beckett CG, Saunders BP, Benson MJ. Long-acting steroid injection after endoscopic dilation of anastomotic Crohn's strictures may improve the outcome: a retrospective case series. Endoscopy 2003, 35:333-337. 10.1055/s-2003-38145, 12664391.
198. Swaminath A, Lichtiger S. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. Inflamm Bowel Dis 2008, 14:213-216. 10.1002/ibd.20318, 18022870.